Skip to main content

Our History

Since the acquisition of ADAM and LIGHT, the Company has identified a prime site in Harley Street, gained planning permission for the site, completed the tender process for the construction, and has made considerable advances in the technical development of LIGHT

A well-considered implementation plan is in place to successfully transform the Company into the undisputed leader for proton therapy

2019
  • Advanced Oncotherapy has been awarded the ISO:13485 certification in Q1:19.
  • During 2019, we completed or announced £16 million in equity investments and £14 million in debt funding
  • The Company is now focused on manufacturing the remaining accelerating structures of LIGHT by Q3:19 and on treating first patients by the end of 2020.

2018
  • During 2018, we completed or announced £37 million in equity investments.
  • LIGHT system able to generate a proton beam with an energy of 52MeV sufficient to treat superficial tumours. Read More.
  • Preparations at the Science and Technology Facilities Council (“STFC”) Daresbury Laboratory are proceeding to plan with the continued commitment of treating first patients by the end of 2020.
  • To illustrate the proton beam acceleration reached with the LIGHT Accelerator in the Testing Facility in Geneva, you can read about the simulated treatment plan of a periocular tumour case. Find out more.

2017
  • During 2017, we completed or announced £33.2 million investment, including £16.8 million of equity investments, alongside our commercial distribution agreement with Yantai CIPU Medical Technology Co. Ltd (“Yantai CIPU”) through their affiliated company Liquid Harmony Ltd to market and sell our LIGHT systems across China and certain neighbouring geographies in Asia.
  • We successfully integrated and tested the first Side Coupled Drift Tube Linac ("SCDTL") with the Radiofrequency Quadrupole ("RFQ") and proton source, three of the four key components of the LIGHT system.
  • Agreement with the UK Government's Science and Technology Facilities Council ("STFC") to establish a UK testing and assembly site for our first operational LIGHT system.
  • The Company also received a payment of £16.5 million relating to the exclusive distribution agreement with Liquid Harmony to market and sell Advanced Oncotherapy's LIGHT system across China, Macau, Taiwan, Hong-Kong and South Korea.

2016
  • Key Board and executive appointments in London and Geneva.
  • Technological progress on the LIGHT system, with delivery and successful integration of the proton source and RFQ, plus delivery and high power testing of linac accelerating modules.
  • Optimisation study by Thales.
  • A Placing and Open Offer raised gross proceeds of £13.4m
  • Granting of planning permission for Harley Street.
  • Sale negotiations in UK, USA, Europe, Asia and Middle East.

2015
  • Harley Street lease with The Howard de Walden Estate for the UK's first proton therapy centre using the LIGHT System.
  • Progress in technical developments.
  • Sale of non-core assets.

2014
  • Supply agreements with ScandiNova, VDL and Toshiba.

2013
  • Step change in Advanced Oncotherapy's activities with the acquisition of ADAM.
  • A number of key appointments were made amongst the executive, non-executive and medical advisory board.
  • Letters of intent secured for the supply of LIGHT machines.

2012
  • CareCapital name changed to Advanced Oncotherapy to reflect the demerger of the property development business and the realignment of the Company's strategy with the aim of capitalising on opportunities in the fields of cancer diagnosis and cancer treatment. This laid the foundations for what Advanced Oncotherapy is today.

2008
  • The Large Hadron Collider (LHC), the world’s largest and most powerful particle accelerator, is turned on. ADAM scientists involved in the project; ADAM's future Executive Chairman integral to its development and management.

2007
  • Foundation of ADAM (Application of Detectors and Accelerators to Medicine), as a spin-off from CERN (the European Organisation for Nuclear Research).
  • The ADAM team, led by Alberto Colussi and Professor Ugo Amaldi, designed and built the first unit of a linear accelerator for treating cancer, known as LIGHT (Linac Image Guided Hadron Technology).

2006
  • IPO of CareCapital on the AIM market.

1994
  • Creation of CareCapital, a company focused on developing, owning and leasing healthcare properties to healthcare operators, primarily in the private sector.